MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 280 filers reported holding MYRIAD GENETICS INC in Q3 2014. The put-call ratio across all filers is 1.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $2,350,000 | -18.4% | 76,813 | -0.2% | 0.22% | -22.8% |
| Q1 2016 | $2,881,000 | -15.0% | 76,963 | -2.0% | 0.28% | -16.2% |
| Q4 2015 | $3,390,000 | +8.1% | 78,538 | -6.1% | 0.34% | +12.6% |
| Q3 2015 | $3,136,000 | +15.0% | 83,678 | +4.3% | 0.30% | +30.2% |
| Q2 2015 | $2,727,000 | -5.0% | 80,243 | -1.1% | 0.23% | -3.7% |
| Q1 2015 | $2,872,000 | +5.9% | 81,118 | +1.9% | 0.24% | +8.6% |
| Q4 2014 | $2,713,000 | -4.7% | 79,640 | +7.9% | 0.22% | -2.6% |
| Q3 2014 | $2,847,000 | -4.6% | 73,818 | -3.7% | 0.23% | -5.0% |
| Q2 2014 | $2,983,000 | +14.9% | 76,643 | +0.9% | 0.24% | +6.2% |
| Q1 2014 | $2,597,000 | +138.3% | 75,968 | +46.2% | 0.23% | +133.0% |
| Q4 2013 | $1,090,000 | -35.0% | 51,968 | -27.2% | 0.10% | -42.6% |
| Q3 2013 | $1,678,000 | -7.4% | 71,400 | +5.8% | 0.17% | -9.1% |
| Q2 2013 | $1,813,000 | – | 67,475 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |